Literature DB >> 1438280

Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme.

J O Ojwang1, A Hampel, D J Looney, F Wong-Staal, J Rappaport.   

Abstract

Ribozymes are RNAs that possess the dual properties of RNA sequence-specific recognition, analogous to conventional antisense molecules, and RNA substrate destruction via site-specific cleavage. The cleavage reaction is catalytic in that more than one substrate molecule is processed per ribozyme molecule. We have designed a hairpin ribozyme that cleaves human immunodeficiency virus type 1 (HIV-1) RNA in the leader sequence (at nucleotides +111/112 relative to the transcription initiation site). The ribozyme was tested in vitro and gave efficient and specific cleavage of RNA containing the leader sequence. To test the antiviral efficacy of this ribozyme, we have cotransfected into HeLa cells HIV-1 proviral DNA and a plasmid expressing the ribozyme from the human beta-actin promoter. HIV-1 expression was inhibited as measured by p24 antigen levels and reduced Tat activity. The antiviral effect of the ribozyme appears to be specific and results from directed RNA cleavage; activity requires both a target sequence and a functional RNA catalytic center. These results suggest that this HIV-1-directed hairpin ribozyme may be useful as a therapeutic agent.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1438280      PMCID: PMC50430          DOI: 10.1073/pnas.89.22.10802

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Autolytic processing of dimeric plant virus satellite RNA.

Authors:  G A Prody; J T Bakos; J M Buzayan; I R Schneider; G Bruening
Journal:  Science       Date:  1986-03-28       Impact factor: 47.728

2.  'Hairpin' catalytic RNA model: evidence for helices and sequence requirement for substrate RNA.

Authors:  A Hampel; R Tritz; M Hicks; P Cruz
Journal:  Nucleic Acids Res       Date:  1990-01-25       Impact factor: 16.971

3.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

4.  Complete nucleotide sequences of functional clones of the AIDS virus.

Authors:  L Ratner; A Fisher; L L Jagodzinski; H Mitsuya; R S Liou; R C Gallo; F Wong-Staal
Journal:  AIDS Res Hum Retroviruses       Date:  1987       Impact factor: 2.205

5.  RNA catalytic properties of the minimum (-)sTRSV sequence.

Authors:  A Hampel; R Tritz
Journal:  Biochemistry       Date:  1989-06-13       Impact factor: 3.162

6.  Gene therapy. Intracellular immunization.

Authors:  D Baltimore
Journal:  Nature       Date:  1988-09-29       Impact factor: 49.962

7.  Injected anti-sense RNAs specifically block messenger RNA translation in vivo.

Authors:  D A Melton
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

8.  Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells.

Authors:  M Matsukura; G Zon; K Shinozuka; M Robert-Guroff; T Shimada; C A Stein; H Mitsuya; F Wong-Staal; J S Cohen; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

9.  Inhibition of human immunodeficiency virus type 1 replication in human T cells stably expressing antisense RNA.

Authors:  G Sczakiel; M Pawlita
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

10.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

View more
  55 in total

1.  RNA double cleavage by a hairpin-derived twin ribozyme.

Authors:  C Schmidt; R Welz; S Müller
Journal:  Nucleic Acids Res       Date:  2000-02-15       Impact factor: 16.971

2.  Cross-clade inhibition of HIV-1 replication and cytopathology by using RNase P-associated external guide sequences.

Authors:  Gunter Kraus; Rebeca Geffin; Gina Spruill; Andrea K Young; Rachel Seivright; Diana Cardona; Jennifer Burzawa; H James Hnatyszyn
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

Review 3.  The hairpin ribozyme. Discovery, mechanism, and development for gene therapy.

Authors:  R Shippy; R Lockner; M Farnsworth; A Hampel
Journal:  Mol Biotechnol       Date:  1999-08       Impact factor: 2.695

Review 4.  RNA interference: from an ancient mechanism to a state of the art therapeutic application?

Authors:  Christoph Arenz; Ute Schepers
Journal:  Naturwissenschaften       Date:  2003-07-23

5.  Optimization of trans-splicing ribozyme efficiency and specificity by in vivo genetic selection.

Authors:  Brian G Ayre; Uwe Köhler; Robert Turgeon; Jim Haseloff
Journal:  Nucleic Acids Res       Date:  2002-12-15       Impact factor: 16.971

6.  Efficient and specific repair of sickle beta-globin RNA by trans-splicing ribozymes.

Authors:  Jonghoe Byun; Ning Lan; Meredith Long; Bruce A Sullenger
Journal:  RNA       Date:  2003-10       Impact factor: 4.942

Review 7.  Cell migration and metastasis as targets of small RNA-based molecular genetic analyses.

Authors:  Eigo Suyama; Hiroaki Kawasaki; Renu Wadhwa; Kazunari Taira
Journal:  J Muscle Res Cell Motil       Date:  2004       Impact factor: 2.698

Review 8.  RNA nanotechnology: engineering, assembly and applications in detection, gene delivery and therapy.

Authors:  Peixuan Guo
Journal:  J Nanosci Nanotechnol       Date:  2005-12

9.  A new antisense tRNA construct for the genetic treatment of human immunodeficiency virus type 1 infection.

Authors:  M A Biasolo; A Radaelli; L Del Pup; E Franchin; C De Giuli-Morghen; G Palu
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

10.  High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G.

Authors:  R K Akkina; R M Walton; M L Chen; Q X Li; V Planelles; I S Chen
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.